Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One probe to rule them all? new liver scanner tested

NCT ID NCT07400289

Knowledge-focused Sponsor: Echosens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 06, 2026 · Updated 3 times

Summary

This study is testing a new single probe for FibroScan, a device that measures liver stiffness to assess disease. Researchers want to see if one probe can work as well as the current two-probe system. About 309 adults with chronic liver disease will take part across France and Hong Kong.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FibroScan device with a single probe
What this could lead to
If successful, this could simplify liver exams by using one probe instead of switching between different sizes.
What could go wrong
This is an early exploratory study focused on measurement accuracy, not treatment. It may not lead to immediate changes in patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 389 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (≥ 18 years of age). * Patient followed with a chronic liver disease. * Adult patient able to give his written consent. * For European sites: patient affiliated to the healthcare system. Exclusion Criteria: * Vulnerable patients. * Patients with ascites. * Patients with heart failure. * Patients with acute hepatitis. * Patients with biliary obstruction.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHRU de Besançon

    NOT_YET_RECRUITING

    Besançon, 25000, France

  • Hôpital Paris Saclay

    NOT_YET_RECRUITING

    Orsay, 91400, France

  • Hôpital St Eloi- CHU Montpellier

    NOT_YET_RECRUITING

    Montpellier, 34090, France

  • Prince of Wales Hospital the Chinese University of Hong Kong

    RECRUITING

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.